Skip to main content
Log in

Immunotherapy of spontaneous mammary tumors in mongrel dogs with autologous tumor cells and neuraminidase

  • Original Articles
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Summary

The effect produced on tumor progression by the injection of either VCN-treated tumor cells or tumor cells mixed with VCN to dogs with spontaneous mammary tumors was investigated. Dogs of different breeds and ages with at least two palpable spontaneous mammary tumors were selected. One tumor was left in the animal for further clinical examination, whereas the other tumor(s) was (were) excised for histologic diagnosis and for preparation of a single-cell suspension. Autologous M-cells were treated with VCN, subsequently extensively washed and injected SC into the neck of the dog on the day of operation and on the next day or different numbers of autologous M tumor cells (105, 106, 107, 5×107, 108) were mixed with different amounts of VCN (0, 0.65, 6.5, 65 mU), and these various mixtures were injected ID at different sites to each dog on the day of operation. This procedure has been called chessboard vaccination (Seiler and Sedlacek, 1978). Altogether 79 dogs were blindly distributed into six groups in three consecutive studies. The results show that the therapeutic effect of the injection of VCN-treated autologous tumor cells depends on the number of tumor cells injected: injection of 2×107 tumor cells repeatedly induced regression of the residual tumor mass (Studies I, II, and III) in most dogs and prevention of metastasis (Study I), while the application of 1×108 tumor cells caused enhanced tumor proliferation in all and early metastasis in most of the dogs (Study I). The injection of 2×106 tumor cells induced only a transient regression, with subsequent progression of the residual mammary tumor (Study II). Repetition of the injection of 2×106 tumor cells three times every 4 weeks did not improve this effect (Study II). The chessboard vaccination proved to be at least as effective as the injection of 2×107 VCN-treated tumor cells (Study III), although 1×108 or more tumor cells had been injected; this number of cells caused tumor enhancement when the cells were treated with VCN only and injected SC (Study I). Moreover, the DTH reaction after ID injection of autologous tumor cells could be increased by the addition of VCN: low numbers of tumor cells and high amounts of VCN or high numbers of tumor cells and low amounts of VCN caused the most pronounced skin response. The relevance of these data to overcoming the risk of tumor enhancement after injection of an inadequate number of VCN-treated tumor cells and the possible diagnostic and therapeutic relevance of the DTH response after chessboard vaccination will be discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  • Albright, L., Madigan, J. C., Gaston, M. R., Houchens, D. P.: Therapy in an intracerebral murine glioma model, using Bacillus Calmette-Guérin, neuraminidase-treated tumor cells, and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea. Cancer Res. 35, 685 (1975).

    Google Scholar 

  • Aminoff, D.: Methods for the quantitative examination of N-acetylneuraminic acid and their application to hydrolysates of sialmucoids. Biochem. J. 81, 384 (1961).

    Google Scholar 

  • Bekesi, J. G., St. Arenault, G., Walter, L., et al.: Immunotherapy of leukemia L1210 cells after neuraminidase treatment. J. Natl. Cancer Inst. 49, 107 (1972).

    Google Scholar 

  • Bekesi, J. G., Roboz, J. P., Walter, L., Holland, J. F.: Stimulation of specific immunity against cancer by neuraminidase-treated tumor cells. Behring Inst. Mitt. 55, 309 (1974).

    Google Scholar 

  • Doré, J. F., Hadjiyannakis, M. J., Guibout, C., Coudert, A., Marholev, L., Imai, K.: Use of enzyme-treated cell in immunotherapy of a murine leukemia. Lancet 1973 VIII, 600.

    Google Scholar 

  • Hampe, J. F., Misdorp, W.: Tumors and dysplasias of the mammary gland. Bull. WHO 50, 111 (1974).

    Google Scholar 

  • Holland, J. F., Bekesi, J. G.: Immunotherapy of human leukemia with neuraminidase-modified cells. Med. Clin. North Am. 60, 539 (1976).

    Google Scholar 

  • Knop, J., Sedlacek, H. H., Seiler, F. R.: Stimulatory effect of Vibrio cholerae neuraminidase on the antibody response against various antigens. Immunology 34, 181 (1978).

    Google Scholar 

  • Kollmorgen, G. M., Killion, J. J., Sansing, W. A., et al.: Immunotherapy with neuraminidase-treated cells and bacillus Calmette-Guérin. Surgery 79, 202 (1976).

    CAS  PubMed  Google Scholar 

  • Lüben, G., Sedlacek, H. H., Seiler, F. R.: Quantitative experiments on the cell membrane binding of neuraminidase. Behring Inst. Mitt. 59, 30 (1976).

    Google Scholar 

  • Nakamura, R. M., Chisari, F. V., Edgington, T. S.: Laboratory tests for diagnosis of autoimmune disease. In: Progress in clinical pathology, p. 177. New York: Grune and Stratton 1975.

    Google Scholar 

  • Petitou, M., Rosenfeld, G., Sinay, P.: A new assay for cell-bound neuraminidase. Cancer Immunol. Immunother. 2, 135 (1977).

    Google Scholar 

  • Porwit-Bobr, Z., Slowik, M., Tomecki, J.: Effect of neuraminidase-treated and mitomycin C-treated polyoma tumor cells on the established tumor growth in CBA mice. I. An attempt at evaluation of polyoma tumor destruction using the distribution of lissamine green method. Folia Histochem. Cytochem. (Krakow) 12, 315 (1974).

    Google Scholar 

  • Ronneberger, H.: Toxicological studies with therapeutically applicable Vibrio cholerae neuraminidase. Dev. Biol. Stand. 38, 413 (1978).

    Google Scholar 

  • Schermer, S.: Blutmorphologie der Laboratoriumstiere, 2. Aufl., p. 85. New York: Johann Ambrosius 1958.

    Google Scholar 

  • Schick, H. J., Zilg, H.: Production and quality control of therapeutically applicable Vibrio cholerae neuraminidase (VCN). Dev. Biol. Stand. 38, 81 (1978).

    Google Scholar 

  • Sedlacek, H. H., Seiler, F. R.: Demonstration of Vibrio cholerae neuraminidase (VCN) on the cell membrane of neuraminidasetreated cells. Behring Inst. Mitt. 55, 254 (1974).

    Google Scholar 

  • Sedlacek, H. H., Meesmann, H., Seiler, F. R.: Regression of spontaneous mammary tumors in dogs after injection of neuraminidasetreated tumor cells. Int. J. Cancer 15, 409 (1975).

    Google Scholar 

  • Sedlacek, H. H., Seiler, F. R., Schwick, H. G.: Neuraminidase and tumor immunotherapy. Klin. Wochenschr. 55, 199 (1977).

    Google Scholar 

  • Sedlacek, H. H., Seiler, F. R.: Spontaneous mammary tumors in mongrel dogs: A relevant model to demonstrate tumor therapeutical success by application of neuraminidase. Dev. Biol. Stand. 38, 399 (1978a).

    Google Scholar 

  • Sedlacek, H. H., Seiler, F. R.: Effect of Vibrio cholerae neuraminidase on the cellular immune response in vivo. In: Immunotherapy of Malignant Diseases. Rainer, H., Borberg, H., Mishler, J. M., Schäfer, U. (eds.), p. 268. Stuttgart: Schattauer 1978b.

    Google Scholar 

  • Seiler, F. R., Sedlacek, H. H.: Alterations of immunological phenomena by neuraminidase: Marked rise in the number of lymphocytes forming rosettes or bearing immunoglobulin receptors. Behring Inst. Mitt. 55, 258 (1974).

    Google Scholar 

  • Seiler, F. R., Sedlacek, H. H.: Chessboard vaccination: A pertinent approach to immunotherapy of cancer with VCN and tumor cells? In: Immunotherapy of Malignant Diseases. Rainer, H., Borberg, H., Mishler, J. M., Schäfer, U. (eds.), p. 479. Stuttgart: Schattauer (1978).

    Google Scholar 

  • Simmons, R. L., Rios, A.: Modified tumor cells in the immunotherapy of solid mammary tumors. Med. Clin. North Am. 60, 551 (1976).

    Google Scholar 

  • Simmons, R. L., Rios, A., Lundgren, G. et al.: Immunospecific regression of methylcholanthrene fibrosarcoma with the use of neuraminidase. Surgery 70, 38 (1971).

    Google Scholar 

  • Spence, R. J., Simon, R. M., Baker, A. R.: Failure of immunotherapy with neuraminidase-treated tumor cell vaccine in mice bearing established 3-methylcholanthrene-induced sarcomas. J. Natl. Cancer Inst. 60, 451 (1978).

    Google Scholar 

  • Wilson, R. E., Sonis, S. T., Godrick, E. A.: Neuraminidase as an adjunct in the treatment of residual systemic tumor with specific immune therapy. Behring Inst. Mitt. 55, 334 (1974).

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Additional information

The abbreviations used in this work are: VCN, vibrio cholerae neuraminidase; M, mitomycin-treated; M-VCN, treated with mitomycin and VCN; DTH, delayed-type hypersensitivity; PBS, phosphate-buffered saline

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sedlacek, H.H., Weise, M., Lemmer, A. et al. Immunotherapy of spontaneous mammary tumors in mongrel dogs with autologous tumor cells and neuraminidase. Cancer Immunol Immunother 6, 47–58 (1979). https://doi.org/10.1007/BF00206016

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00206016

Keywords

Navigation